2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Palliative Care, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Bacterial, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3350 Factors associated with quality of life during early treatment in older adults with acute myeloid leukemia

Zoe Lorene Andrews, MSc, Todd A. Schwartz, DrPH2, Ya-Ning Chan, PhD, RN3, Danielle S Anderson4, Daniel Ross Richardson, MD, MSc5, Mackenzi Pergolotti, Ph.D., OTR/L6, Victoria Rose Crowder, PhD, RN7, Dawn Klemm, DNP, AGNP, RN8, Leonora Tisdale, DNP, RN9, Ashley Bryant, PhD, RN, OCN, FAAN10, Tamryn LaShea Fowler, PhD, RN, MPH, MSN11
1 Morehouse School of Medicine, Atlanta, Georgia, United States, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
2 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
3 Duke University, Durham, North Carolina, United States
4 University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
5 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
6 Select Medical, Chapel Hill, North Carolina, United States, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
7 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
8 Cone Health, Mebane, North Carolina, United States, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
9 Cone Health, Mebane, North Carolina, United States, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
10 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
11 University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Background

Older adults with newly diagnosed acute myeloid leukemia (AML) experience substantial symptom burden, functional decline, and impaired quality of life (QOL) during treatment. Lower-intensity regimens are predominantly delivered in the outpatient setting, shifting much of AML care to the home. This model requires patients to manage symptoms, medications, and communication with clinicians between visits. Limited physiologic and functional reserve may heighten vulnerability to fatigue and functional decline, particularly during Cycles 1 and 2. Identifying modifiable clinical, behavioral, and financial factors associated with early QOL may inform supportive care for older adults receiving outpatient AML therapy. We examined associations of patient activation, functional status, fatigue, disease burden, participation in meaningful activity, and financial difficulties with QOL during early AML treatment.

Methods

We conducted a secondary analysis of the PAlliative and Collaborative Care inTervention (PACT) pilot study, a prospective sequential cohort study of adults aged ≥60 years with newly diagnosed AML receiving lower-intensity therapy. QOL was assessed using the EORTC QLQ-C30 global health status/QOL scale. Patient activation, defined as patients’ knowledge, skills, and confidence to manage their health and healthcare, was measured using the 13-item Patient Activation Measure; fatigue using the PRO-CTCAE; functional status using the Karnofsky Performance Status (KPS); leukemia-specific disease burden using the FACT-Leukemia Additional Concerns subscale; possibilities for meaningful activity using the Possibilities for Activity Scale (PActS); and financial difficulties using the EORTC QLQ-C30 financial difficulties item. Descriptive statistics and Pearson correlations examined bivariate associations with Cycle 2 QOL. Separate linear regression models evaluated associations of patient activation, fatigue, and financial difficulties with Cycle 2 QOL. Adjusted models included Cycle 1 QOL and study group.

Results

Among 39 enrolled patients, 29 had QOL data at Cycle 2. Their mean age was 75.3 years (SD=7.2; range, 64–89); 69.0% were male, 82.8% were White, 93.1% were non-Hispanic, and 72.4% were married or partnered. Most had at least a high school education (93.1%), 34.5% were employed before diagnosis or treatment, and all had health insurance. Mean QOL was 54.4 at Cycle 1 and 62.4 at Cycle 2. In bivariate analyses, higher Cycle 2 QOL was significantly associated with lower fatigue (r=−0.46, p=0.01), higher KPS (r=0.52, p=0.005), lower disease burden (FACT-Leu; r=0.76, p<0.0001), and greater participation in meaningful activity (PActS; r=0.53, p=0.003). Patient activation was positively but not significantly correlated with QOL (r=0.28, p=0.17), while financial difficulties were inversely correlated with QOL (r=−0.32, p=0.09). In unadjusted regression models, greater fatigue was significantly associated with lower Cycle 2 QOL (β=−0.34, p=0.01); financial difficulties (β=−0.20, p=0.09) and patient activation (β=0.27, p=0.17) were not significant. In adjusted models, Cycle 1 QOL remained significantly associated with Cycle 2 QOL (β range=0.33–0.41, all p<0.05). Associations with fatigue (β=−0.18, p=0.22), financial difficulties (β=−0.16, p=0.12), and patient activation (β=0.22, p=0.21) were attenuated and no longer significant.

Conclusions

Among older adults receiving predominantly outpatient, lower-intensity therapy for newly diagnosed AML, better functional status, lower fatigue, lower leukemia-specific disease burden, and greater participation in meaningful activity were associated with better concurrent QOL during early treatment. Patient activation and financial difficulties showed potentially meaningful but non-significant associations, while initial QOL was consistently associated with subsequent QOL. These findings support further investigation of function, fatigue, disease burden, meaningful activity, patient activation, and financial difficulties as potentially modifiable supportive care targets for older adults newly diagnosed with AML undergoing lower-intensity therapy.

Zoe Lorene Andrews, MSc: No relevant conflicts of interest to declare.